Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.72 USD | -0.79% | -2.29% | -3.72% |
Mar. 18 | Health Care Up as Traders Await Policy Statement -- Health Care Roundup | DJ |
Mar. 18 | Stocks downbeat before central bank rate storm | AN |
Financials (USD)
Sales 2024 * | 60.42B | Sales 2025 * | 63.09B | Capitalization | 158B |
---|---|---|---|---|---|
Net income 2024 * | 7.89B | Net income 2025 * | 12.59B | EV / Sales 2024 * | 3.37 x |
Net Debt 2024 * | 45.61B | Net Debt 2025 * | 42.35B | EV / Sales 2025 * | 3.18 x |
P/E ratio 2024 * |
18.2
x | P/E ratio 2025 * |
12.3
x | Employees | 88,000 |
Yield 2024 * |
6.13% | Yield 2025 * |
6.29% | Free-Float | 58.92% |
Latest transcript on Pfizer, Inc.
1 day | -0.02% | ||
1 week | +1.84% | ||
Current month | +4.37% | ||
1 month | +0.36% | ||
3 months | +4.09% | ||
6 months | -18.64% | ||
Current year | -3.72% |
Managers | Title | Age | Since |
---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 62 | 92-12-31 |
David Denton
DFI | Director of Finance/CFO | 59 | 22-05-01 |
Jeff Settleman
CTO | Chief Tech/Sci/R&D Officer | - | 19-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 20-03-31 | |
Ronald Blaylock
BRD | Director/Board Member | 64 | 17-02-22 |
Shantanu Narayen
BRD | Director/Board Member | 60 | 13-09-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
14.74% | 227 M€ | +9.20% | - | |
9.37% | 18 M€ | +4.89% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 27.72 | -0.79% | 36,203,597 |
24-03-15 | 27.94 | -0.68% | 75,727,854 |
24-03-14 | 28.13 | -0.32% | 36,427,957 |
24-03-13 | 28.22 | +0.75% | 39,272,983 |
24-03-12 | 28.01 | -1.27% | 48,758,226 |
Delayed Quote Nyse, March 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.72% | 158B | |
+30.83% | 679B | |
+30.96% | 589B | |
+0.01% | 381B | |
+15.18% | 314B | |
+11.39% | 308B | |
+0.78% | 212B | |
-6.09% | 210B | |
-2.92% | 203B | |
-5.94% | 144B |